Breast Cancer Trial, Not Yet Recruiting NCT07077018 Sponsor: Guangdong Provincial People's Hospital Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Not Yet Recruiting

NCT07077018
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with a specific type of breast cancer (called invasive ductal carcinoma) that is ER-positive and HER2-negative, confirmed by a tissue sample, and meets at least one of the following: the tumour is a certain size with lymph node involvement and a moderate or high grade (with low hormone receptor levels); the cancer has spread to multiple lymph nodes, or is high grade, or has a high cell growth rate (Ki67 ≥40%); or the tumour is large (T3–T4) (confirm with trial site for exact staging details)
  • People aged 18 to 75 years at the time of joining the trial
  • People with a body mass index (BMI) of 18.5 or above (a basic measure of body weight relative to height)
  • People whose blood counts are within acceptable ranges, including white blood cells, neutrophils (infection-fighting cells), and platelets (clotting cells)
  • People whose liver and kidney function are within acceptable ranges based on blood test results
  • People who are reasonably well and able to carry out daily activities, as measured by a standard health scale (ECOG score of 0–2, meaning fully active to capable of self-care)
  • People who are willing and able to sign a written consent form

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a history of any other cancer, including cancer in the other breast
  • People who have already received any chemotherapy before surgery for their current breast cancer diagnosis
  • People who have poorly controlled diabetes (requiring insulin or tablets) or a thyroid condition requiring medication
  • People who have an active autoimmune disease that requires medication to suppress the immune system
  • People who are currently taking antipsychotic medications
  • People who have a known allergy or sensitivity to ingredients used in the fasting-mimicking diet (FMD) used in this trial, such as soy protein, milk protein, or nuts
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kun Wang, Guangdong Provincial People's Hospital

Phone: 008613922118086

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Guangdong Provincial People's Hospital
Registry
ClinicalTrials.gov
Start date
12 July 2025
Est. completion
30 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pathological complete response (pCR) rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov